Effects of Previous Infection and Vaccination on Sympt

New England Journal of Medicine
387, 21-34
DOI: 10.1056/nejmoa2203965

Citation Report

#	Article	IF	Citations
6	Dawn of the hybrid immunity era in long-term care facilities. The Lancet Healthy Longevity, 2022, 3, e451-e452.	4.6	0
7	One coronavirus infection wards off another â€" but only if itâ€™s a similar variant. Nature, 0, , .	27.8	5
11	Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands. International Journal of Infectious Diseases, 2022, 122, 636-643.	3.3	22
13	Dengue and COVID-19: two sides of the same coin. Journal of Biomedical Science, 2022, 29, .	7.0	16
14	Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Regionâ€™s Population. International Journal of Environmental Research and Public Health, 2022, 19, 8179.	2.6	6
17	Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. CKJ: Clinical Kidney Journal, 2022, 15, 1816-1828.	2.9	9
23	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Journal of Virology, 2022, 96, .	3.4	12
24	A Critique of EU Digital COVID-19 Certificates: Do Vaccine Passports Endanger Privacy?. , 2022, , .		2
27	Severe pulmonary hemorrhage in a 3â€weekâ€old neonate with <scp>COVID</scp> â€19 infection: A case report. Clinical Case Reports (discontinued), 2022, 10, .	0.5	0
29	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nature Communications, 2022, 13, .	12.8	49
31	Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study. Clinical Microbiology and Infection, 2023, 29, 101-106.	6.0	16
33	Balancing the medical and social needs of children during the <scp>COVID</scp> â€19 pandemic. Medical Journal of Australia, 0, , .	1.7	2
34	SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity. Journal of Experimental Medicine, 2022, 219, .	8.5	72
35	SARS-CoV-2-specific TÂcells in the changing landscape of the COVID-19 pandemic. Immunity, 2022, 55, 1764-1778.	14.3	63
36	Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Eurosurveillance, 2022, 27, .	7.0	16
37	Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. International Journal of Infectious Diseases, 2022, 124, 96-103.	3.3	15
38	The importance of booster vaccination in the context of Omicron wave. Frontiers in Immunology, 0, 13, .	4.8	9
39	Act Early and at the Right Location: SARS-CoV-2 T Cell Kinetics and Tissue Localization. International Journal of Molecular Sciences, 2022, 23, 10679.	4.1	5

#	Article	IF	Citations
40	Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022. Emerging Infectious Diseases, 2022, 28, 2119-2121.	4.3	6
41	Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. Journal of Clinical Virology, 2022, 156, 105273.	3.1	19
44	Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. EClinicalMedicine, 2022, 53, 101655.	7.1	21
45	Mind over what matters: How training in emotional self-regulation can strengthen the immune response in lonely elders. Brain, Behavior, and Immunity, 2022, 106, 231-232.	4.1	0
46	Effectiveness of BNT162b2 and CoronaVac COVID-19 Vaccination Against Asymptomatic and Symptomatic Infection of SARS-CoV-2 Omicron BA.2 in Hong Kong. SSRN Electronic Journal, 0, , .	0.4	3
47	Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study. SSRN Electronic Journal, 0, , .	0.4	3
48	Plaque-Neutralizing Antibody to BA.2.12.1, BA.4 and BA.5 in Individuals with Three Doses of Biontech or Coronavac Vaccines, Natural Infection and Breakthrough Infection. SSRN Electronic Journal, 0, , .	0.4	0
49	Trends in Confirmed COVID-19 Cases in the Korean Military Before and After the Emergence of the Omicron Variant. Journal of Korean Medical Science, 2022, 37, .	2.5	2
50	SARS-CoV-2 Vaccination in Solid-Organ Transplant Recipients. Vaccines, 2022, 10, 1430.	4.4	6
53	Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. Vaccine, 2022, 40, 7195-7200.	3.8	17
54	Covid-19 Vaccines â€" Immunity, Variants, Boosters. New England Journal of Medicine, 2022, 387, 1011-1020.	27.0	266
55	COVID-19 and isolation: Risks and implications in the scenario of new variants. Brazilian Journal of Infectious Diseases, 2022, 26, 102703.	0.6	2
57	A Proposal to Refer to Four Coronaviruses of Limited Human Virulence â€œCommon Cold Coronavirusesâ€• Journal of Infectious Diseases, 2022, 226, 2047-2049.	4.0	5
58	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. Journal of Travel Medicine, 2022, 29, .	3.0	54
60	<scp>COVID</scp>â€19: Vaccineâ€induced immune thrombotic thrombocytopenia. European Journal of Haematology, 2022, 109, 619-632.	2.2	3
62	On the Origins of Omicronâ€™s Unique Spike Gene Insertion. Vaccines, 2022, 10, 1509.	4.4	10
64	Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. Lancet Infectious Diseases, The, 2023, 23, 45-55.	9.1	55
65	Hybrid immunity and strategies for COVID-19 vaccination. Lancet Infectious Diseases, The, 2023, 23, 2-3.	9.1	21

#	Article	IF	Citations
66	Immune Evasion of SARS-CoV-2 Omicron Subvariants. Vaccines, 2022, 10, 1545.	4.4	19
67	SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis. Gut, 2023, 72, 1995-1996.	12.1	2
69	Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants. Vaccines, 2022, 10, 1596.	4.4	1
70	Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses. Cell, 2022, 185, 4333-4346.e14.	28.9	32
71	SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil. PLoS Neglected Tropical Diseases, 2022, 16, e0010337.	3.0	9
73	Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respiratory Medicine,the, 2023, 11, 176-187.	10.7	17
74	Vaccineâ€induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology, 2023, 95, .	5.0	19
75	BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Reports, 2022, 41, 111544.	6.4	17
76	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med, 2022, 3, 838-847.e3.	4.4	26
77	Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. New England Journal of Medicine, 2022, 387, 1620-1622.	27.0	89
78	SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask. Yonsei Medical Journal, 2022, 63, 977.	2.2	7
79	How will previous infection or current vaccination strategies protect us from future SARSâ€CoVâ€2 variant infections?. , 2022, 1, .		0
80	Protection against Omicron from Vaccination and Previous Infection in a Prison System. New England Journal of Medicine, 2022, 387, 1770-1782.	27.0	40
82	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. Lancet Infectious Diseases, The, 2023, 23, 295-306.	9.1	14
84	A Scoping Review of Three Dimensions for Long-Term COVID-19 Vaccination Models: Hybrid Immunity, Individual Drivers of Vaccinal Choice, and Human Errors. Vaccines, 2022, 10, 1716.	4.4	1
85	Original antigen sin and COVID-19: implications for seasonal vaccination. Expert Opinion on Biological Therapy, 2022, 22, 1353-1358.	3.1	5
86	Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. Gastroenterology, 2023, 164, 300-303.e3.	1.3	6
87	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. New England Journal of Medicine, 2022, 387, 1865-1876.	27.0	37

#	Article	IF	Citations
89	Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2. New England Journal of Medicine, 2022, 387, 1716-1718.	27.0	50
91	COVID-19 convalescent plasma therapy through the lens of the third year of the pandemic. Clinical Microbiology and Infection, 2022, , .	6.0	1
93	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-NaÃ¯ve and Convalescent BNT162b2 Recipients. Vaccines, 2022, 10, 1904.	4.4	6
94	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe, The, 2022, 3, e944-e955.	7.3	34
95	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature, 2023, 613, 558-564.	27.8	159
96	Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerlandâ€"A multicentre cohort study. PLoS Medicine, 2022, 19, e1004125.	8.4	11
97	Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection. Viruses, 2022, 14, 2458.	3.3	8
98	Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatology, The, 2023, 5, e36-e46.	3.9	10
100	Prevalence of SARS-CoV-2 antibodies after the Omicron surge, Kingston, Jamaica, 2022. Journal of Clinical Virology Plus, 2022, 2, 100124.	1.0	3
101	An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. Vaccine, 2023, 41, 109-118.	3.8	17
102	Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination. Journal of Infectious Diseases, 2023, 227, 651-662.	4.0	7
103	Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada. International Journal of Infectious Diseases, 2023, 127, 69-76.	3.3	3
104	SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers. Infection and Chemotherapy, 2022, 54, 774.	2.3	3
105	The Omicron-transformer: Rise of the subvariants in the age of vaccines. Annals of the Academy of Medicine, Singapore, 2022, 51, 712-729.	0.4	9
107	Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infectionâ€"Final Update of a Living, Rapid Review. Annals of Internal Medicine, 2023, 176, 85-91.	3.9	6
108	Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination. Lancet Infectious Diseases, The, 2023, 23, 382-383.	9.1	1
111	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Medicine, 2022, 19, e1004037.	8.4	28
112	Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021â€"March, 2022: a national, observational, test-negative, case-control study. Lancet Infectious Diseases, The, 2023, 23, 435-444.	9.1	47

#	Article	IF	Citations
113	Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 15303.	2.6	3
114	Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. Nature Communications, 2022, 13, .	12.8	5
115	COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics, 2024, 50, 126-138.	1.8	16
116	Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity. Vaccine, 2023, 41, 892-902.	3.8	3
118	Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative caseâ€“control analysis. PLoS Medicine, 2022, 19, e1004136.	8.4	7
119	The Epidemiology of Long Coronavirus Disease in US Adults. Clinical Infectious Diseases, 2023, 76, 1636-1645.	5.8	37
120	Analysis of 394 COVID-19 cases infected with Omicron variant in Shenzhen: impact of underlying diseases to patientâ€™s symptoms. European Journal of Medical Research, 2022, 27, .	2.2	0
121	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. Nature Communications, 2022, 13, .	12.8	17
122	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. Pathogens and Immunity, 2022, 7, 93-119.	3.1	0
124	Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infectious Diseases, The, 2023, 23, 421-434.	9.1	24
126	Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine. Vaccines, 2022, 10, 2102.	4.4	1
128	Protection against Omicron from Vaccination and Previous Infection. New England Journal of Medicine, 2023, 388, 95-96.	27.0	0
130	Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study. Vaccines, 2023, 11, 25.	4.4	3
131	Current evidence of COVID-19 vaccination-related cardiovascular events. Postgraduate Medicine, 2023, 135, 102-120.	2.0	5
133	Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. Cmaj, 2022, 194, E1599-E1609.	2.0	25
134	Hybrid immunity and protection against infection during the Omicron wave in Malta. Emerging Microbes and Infections, 2023, 12, .	6.5	2
135	Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naÃ¯ve and previously-infected individuals. Vaccine, 2023, 41, 879-882.	3.8	2
136	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. Journal of Infection and Public Health, 2023, 16, 250-256.	4.1	10

#	Article	IF	Citations
137	Time from last immunity event against infection during Omicron-dominant period in Malaysia. International Journal of Infectious Diseases, 2023, 128, 98-101.	3.3	3
138	Impact of SARS-CoV-2 exposure history on the TÂcell and IgG response. Cell Reports Medicine, 2023, 4, 100898.	6.5	13
139	Towards the light at the end of the tunnel: Changes in clinical settings and political measures regarding COVID-19 from 2021, and future perspectives in Japan. Global Health & Medicine, 2022, 4, 327-331.	1.4	8
140	Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. Vaccines, 2022, 10, 2074.	4.4	3
142	COVID-19 patientsâ€™ clinical profile and outcome with respect to their vaccination status: A prospective observational multicentre cohort study during third wave in Western India. Indian Journal of Medical Microbiology, 2023, 41, 28-32.	0.8	2
143	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nature Communications, 2023, 14, .	12.8	54
144	Prevalent and immunodominant CD8 TÂcell epitopes are conserved in SARS-CoV-2 variants. Cell Reports, 2023, 42, 111995.	6.4	12
145	Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nature Medicine, 2023, 29, 358-365.	30.7	108
147	Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nature Communications, 2023, 14, .	12.8	15
148	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. Infectious Diseases and Therapy, 2023, 12, 367-387.	4.0	22
150	Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nature Medicine, 2023, 29, 348-357.	30.7	74
151	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. International Journal of Infectious Diseases, 2023, 128, 112-120.	3.3	6
152	Omicron. , 2023, , 367-413.		0
153	Management of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Onboard a U.S. Navy Hospital Ship Amid a Global Omicron Surge. Military Medicine, 0, , .	0.8	0
154	A longitudinal study of SARS-CoV-2 antibody response in a subset of United States blood donors. Open Forum Infectious Diseases, 0, , .	0.9	0
155	The COVID-19 Pandemicâ€”A Potential Role for Antivirals in Mitigating Pandemics. Viruses, 2023, 15, 303.	3.3	3
156	Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination. Vaccines, 2023, 11, 242.	4.4	4
158	A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529). Vaccines, 2023, 11, 224.	4.4	21

#	Article	IF	Citations
159	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccinationâ€"Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines, 2023, 11, 370.	3.2	15
162	Reply to â€œPatients With Inflammatory Bowel Disease on Anti-TNF Therapy and COVID-19 Vaccinationâ€• Inflammatory Bowel Diseases, 0, , .	1.9	0
163	Vaccine Effectiveness Against the SARS-CoV-2 B.1.1.529 Omicron Variant in Solid Organ and Islet Transplant Recipients in England: A National Retrospective Cohort Study. Transplantation, 2023, 107, 1124-1135.	1.0	5
164	Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers. Vaccines, 2023, 11, 283.	4.4	3
165	Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infectious Diseases, The, 2023, 23, 556-567.	9.1	242
168	The emergence of new variants and sub-variants of SARS-CoV-2 and the effectiveness of vaccines. Payesh, 2023, 22, 105-108.	0.2	0
169	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. Tropical Medicine and Infectious Disease, 2023, 8, 185.	2.3	0
170	Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Vaccine, 2023, 41, 2234-2242.	3.8	7
171	Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. Viruses, 2023, 15, 917.	3.3	1
172	Spheromers reveal robust TÂcell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ TÂcell responses post SARS-CoV-2 infection. Immunity, 2023, 56, 864-878.e4.	14.3	28
173	Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021â€"June 2022): secondary analysis of a prospective cohort study. Lancet Regional Health - Europe, The, 2023, 27, 100584.	5.6	6
174	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. IScience, 2023, 26, 106562.	4.1	1
175	Observed negative vaccine effectiveness could be the canary in the coal mine for biases in observational COVID-19 studies. International Journal of Infectious Diseases, 2023, 131, 111-114.	3.3	6
176	Long-term follow-up of patients after COVID-19: adherence to SARS-CoV-2 vaccination and immune status. Profilakticheskaya Meditsina, 2022, 25, 88.	0.6	2
177	Defending against SARS-CoV-2: The T cell perspective. Frontiers in Immunology, 0, 14, .	4.8	20
178	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. Heliyon, 2023, 9, e13285.	3.2	4
179	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. European Journal of Epidemiology, 2023, 38, 237-242.	5.7	7
180	Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal. Emerging Infectious Diseases, 2023, 29, 569-575.	4.3	5

#	Article	IF	Citations
181	Comparable humoral and cellular immunity against Omicron variant BA.4/5 of onceâ€boosted BA.1/2 convalescents and twiceâ€boosted COVIDâ€19â€naÃ¯ve individuals. Journal of Medical Virology, 2023, 95, .	5.0	2
182	Comparison of Two Commercially Available Interferon-Î³ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers. Diagnostics, 2023, 13, 637.	2.6	4
183	Inflammatory Biomarkers Differ among Hospitalized Veterans Infected with Alpha, Delta, and Omicron SARS-CoV-2 Variants. International Journal of Environmental Research and Public Health, 2023, 20, 2987.	2.6	5
184	Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection. Cellular Immunology, 2023, 385, 104689.	3.0	1
185	Early vs Deferred Nonâ€“Messenger RNA COVID-19 Vaccination Among Chinese Patients With a History of Inactive Uveitis. JAMA Network Open, 2023, 6, e2255804.	5.9	2
186	Estimating the share of SARS-CoV-2-immunologically naÃ¯ve individuals in Germany up to June 2022. Epidemiology and Infection, 2023, 151, .	2.1	4
187	Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med, 2023, 4, 191-215.e9.	4.4	16
188	Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet, The, 2023, 401, 833-842.	13.7	151
190	Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19â€Associated Encounters in Adults During Delta and Omicron Predominance. Journal of Infectious Diseases, 2023, 227, 1348-1363.	4.0	4
191	Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. American Journal of Infection Control, 2023, 51, 1049-1055.	2.3	4
192	Evaluation of the Abbott Panbioâ„¢ COVID-19 antigen detection rapid diagnostic test among healthcare workers in elderly care. PLoS ONE, 2023, 18, e0276244.	2.5	3
194	Lung tropism in hospitalized patients following infection with SARS-CoV-2 variants from D614G to Omicron BA.2. Communications Medicine, 2023, 3, .	4.2	5
195	Prevention of COVID-19 during youth ice hockey. Applied Physiology, Nutrition and Metabolism, 0, , .	1.9	0
196	SARSâ€CoVâ€2 in animals: susceptibility of animal species, risk for animal and public health, monitoring, prevention and control. EFSA Journal, 2023, 21, .	1.8	16
197	Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant. Infection and Drug Resistance, 0, Volume 16, 1159-1170.	2.7	4
198	SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplantation, 2023, 58, 567-580.	2.4	12
199	Development and validation of a prognostic model based on immune variables to early predict severe cases of SARS-CoV-2 Omicron variant infection. Frontiers in Immunology, 0, 14, .	4.8	1
200	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Expert Review of Vaccines, 2023, 22, 288-298.	4.4	4

#	Article	IF	Citations
202	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infectious Diseases, The, 2023, 23, 816-827.	9.1	35
203	Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infectious Diseases, The, 2023, 23, 799-805.	9.1	31
204	Comparative complete scheme and booster effectiveness of COVIDâ€19 vaccines in preventing SARSâ€CoVâ€2 infections with SARSâ€CoVâ€2 Omicron (BA.1) and Delta (B.1.617.2) variants: A caseâ€“case study based on electronic health records. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	0
209	Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe, The, 2023, 4, e309-e318.	7.3	26
210	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. IScience, 2023, 26, 106457.	4.1	3
211	Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. Journal of Immunology, 2023, 210, 1236-1246.	0.8	4
212	Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. Nature Communications, 2023, 14, .	12.8	17
213	Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study. Infection, 2023, 51, 1093-1102.	4.7	3
214	Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nature Communications, 2023, 14, .	12.8	8
215	COVID-19 patient and personal safety â€“ lessons learnt for pandemic preparedness and the way to the next normal. Antimicrobial Resistance and Infection Control, 2023, 12, .	4.1	0
216	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. Frontiers in Public Health, 0, 11, .	2.7	7
217	Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. International Journal of Infectious Diseases, 2023, 132, 72-79.	3.3	4
218	Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. Lancet Microbe, The, 2023, 4, e495-e505.	7.3	3
219	SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 2023, 11, 849.	4.4	12
220	Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	11
221	SARSâ€CoVâ€2 vaccine antibody response and breakthrough infections in transplant recipients. Journal of Medical Virology, 2023, 95, .	5.0	4
222	Safety and effectiveness of vaccines against COVID-19 in children aged 5â€“11 years: a systematic review and meta-analysis. The Lancet Child and Adolescent Health, 2023, 7, 379-391.	5.6	19
225	Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK. Nature Communications, 2023, 14, .	12.8	10

#	Article	IF	Citations
226	Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia. Infectious Diseases and Therapy, 2023, 12, 1237-1264.	4.0	5
227	Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study. International Journal of Infectious Diseases, 2023, , .	3.3	1
229	All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic. BMJ Global Health, 2023, 8, e012291.	4.7	11
230	Key Lessons from COVID-19: A Narrative Review Describing Qatarâ€™s Multifactorial Approach in Executing a Vaccination Campaign. Vaccines, 2023, 11, 953.	4.4	0
231	Optimizing COVID-19 Vaccination Strategy in Pediatric Kidney Transplant Recipients: Humoral and Cellular Response to SARS-CoV-2 mRNA Vaccination. Transplant International, 0, 36, .	1.6	1
232	SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Frontiers in Immunology, 0, 14, .	4.8	22
233	Three phases of increasing complexity in estimating vaccine protection. International Journal of Epidemiology, 2023, 52, 1299-1302.	1.9	1
234	Prior SARSâ€CoVâ€2 infection and COVIDâ€19 vaccine effectiveness against outpatient illness during widespread circulation of SARSâ€CoVâ€2 Omicron variant, US Flu VE network. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	5
235	SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients: What Do We Know, and What Remains to Be Determined?. Hemato, 2023, 4, 170-183.	0.6	1
237	Incidence of and risk factors for suspected COVID-19 reinfection in Kyoto City: a population-based epidemiological study. European Journal of Clinical Microbiology and Infectious Diseases, 2023, 42, 973-979.	2.9	4
238	Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunity. Journal of Infection and Public Health, 2023, 16, 1262-1268.	4.1	1
239	Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies. Frontiers in Public Health, 0, 11, .	2.7	9
240	De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 0, , .	4.0	0
241	Mild SARS-CoV-2 infection results in long-lasting microbiota instability. MBio, 0, , .	4.1	2
242	Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals. Clinical and Experimental Immunology, 2024, 215, 268-278.	2.6	0
243	T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets. Frontiers in Immunology, 0, 14, .	4.8	2
245	Broad-spectrum pan-genus and pan-family virus vaccines. Cell Host and Microbe, 2023, 31, 902-916.	11.0	6
246	Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. Lancet Infectious Diseases, The, 2023, 23, 1257-1265.	9.1	9

#	Article	IF	Citations
247	Analysis of Veno-Venous Extracorporeal Membrane Oxygenation for COVID-19 Compared to Non-COVID Etiologies. Annals of Surgery, 0, Publish Ahead of Print, .	4.2	0
248	Clinical symptoms of SARSâ€CoVâ€2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccinationâ€"A prospective multicentre cohort of health professionals (SURPRISE study). Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	3
249	Humoral Immunity of Unvaccinated COVID-19 Recovered vs. NaÃ¯ve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study. Microorganisms, 2023, 11, 1628.	3.6	0
250	Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV. Viruses, 2023, 15, 1435.	3.3	1
251	Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice. Npj Vaccines, 2023, 8, .	6.0	2
252	Efficacy of <scp>COVID</scp>â€19 vaccination in adult patients with sickle cell disease during the Omicron wave in France. European Journal of Haematology, 2023, 111, 509-512.	2.2	3
253	Impact of SARS-CoV2 infection on mortality and hospitalization in nursing home residents during the â€œOmicron eraâ€• Aging Clinical and Experimental Research, 2023, 35, 1393-1399.	2.9	0
254	Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine, 2023, 92, 104585.	6.1	17
256	The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant â€" Guangdong Province, China, December 2022 to January 2023. China CDC Weekly, 2023, 5, 391-396.	2.3	6
257	Lethality of <scp>SARSâ€CoV</scp>â€2 infectionâ€"a comparative autopsy study focusing on <scp>COVID</scp>â€19 development and virus variants. Histopathology, 2023, 83, 242-251.	2.9	5
259	Frontline Worker Safety in the Age of COVID-19: A Global Perspective. Journal of Patient Safety, 0, Publish Ahead of Print, .	1.7	1
260	BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. The Lancet Child and Adolescent Health, 2023, 7, 463-470.	5.6	11
261	Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine. Clinical Microbiology and Infection, 2023, 29, 1201.e1-1201.e5.	6.0	4
262	Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection. Nature Communications, 2023, 14, .	12.8	1
263	The Omicron Variant Reinfection Risk among Individuals with a Previous SARS-CoV-2 Infection within One Year in Shanghai, China: A Cross-Sectional Study. Vaccines, 2023, 11, 1146.	4.4	2
264	COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. Eurosurveillance, 2023, 28, .	7.0	0
267	Superspreading of SARS-CoV-2 Omicron BA.2.23 among vaccinated Finnish adults: symptomatic COVID-19 only contracted by those without recent infection. Epidemiology and Infection, 2023, 151, .	2.1	0
268	Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models. Virologica Sinica, 2023, 38, 787-800.	3.0	3

#	Article	IF	Citations
269	Effectiveness of the strain 919 bovine ephemeral fever virus vaccine in the face of a real-world outbreak: A field study in Israeli dairy herds. Vaccine, 2023, 41, 5126-5133.	3.8	1
270	Long- and short-term effects of cross-immunity in epidemic dynamics. Chaos, Solitons and Fractals, 2023, 174, 113800.	5.1	0
271	Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection. Science Advances, 2023, 9, .	10.3	4
272	Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project. Journal of Epidemiology and Global Health, 2023, 13, 577-588.	2.9	5
273	Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ, The, 0, , e074325.	6.0	4
274	COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients. Biomedicines, 2023, 11, 2055.	3.2	2
275	Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine, 2023, 95, 104734.	6.1	5
276	Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Lancet Infectious Diseases, The, 2023, 23, 1349-1359.	9.1	15
277	Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nature Communications, 2023, 14, .	12.8	4
278	Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. Lancet Microbe, The, 2023, 4, e670-e682.	7.3	4
279	SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds. Journal of Infectious Diseases, 2023, 228, 1311-1313.	4.0	11
280	Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant. Journal of Clinical Medicine, 2023, 12, 5572.	2.4	5
281	Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nature Communications, 2023, 14, .	12.8	6
282	Hybrid Immunity Provides the Best COVID-19 Humoral Response in Immunocompromised Patients with or without SARS-CoV-2 Infection History. Vaccines, 2023, 11, 1380.	4.4	2
283	Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Vaccination for Negative Conversion Time of Nucleic Acid in Nonsevere COVID-19 Patients Infected by SARS-CoV-2 Omicron Variant. International Journal of Clinical Practice, 2023, 2023, 1-8.	1.7	1
284	Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12â€“17 Years against COVID-19 Infection in Qatar. Vaccines, 2023, 11, 1522.	4.4	1
285	Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing. Frontiers in Immunology, 0, 14, .	4.8	0
286	Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. EClinicalMedicine, 2023, 62, 102102.	7.1	3

#	Article	IF	Citations
287	Outcomes and characteristics of patients hospitalized for COVID-19 in British Columbia, Ontario and Quebec during the Omicron wave. CMAJ Open, 2023, 11, E672-E683.	2.4	2
288	Effectiveness of first and second boost COVID-19 vaccination in healthy adults during BA.5.2/BF.7 surge in China. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
289	Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nature Communications, 2023, 14, .	12.8	13
290	Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province. Frontiers in Public Health, 0, 11, .	2.7	1
291	SARS-CoV-2 infection in 3,241 School working staffs: Impact of SARS CoV-2 variants of concern [Wild, B.1.1.7 and Omicron]. PLoS ONE, 2023, 18, e0291989.	2.5	1
292	Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study. Lancet Infectious Diseases, The, 2023, 23, 1343-1348.	9.1	18
293	Customizably designed multibodies neutralize SARS-CoV-2 in a variant-insensitive manner. Frontiers in Immunology, 0, 14, .	4.8	0
294	Evolution of seroprevalence to SARSâ€CoVâ€2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Crossâ€sectional and longitudinal studies. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	0
296	Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Caseâ€"Control Study Based on the French National Health Data System. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
297	Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. International Journal of Infectious Diseases, 2023, 136, 81-90.	3.3	2
299	Monitoring strategy of COVIDâ€19 vaccination in dialysis patients based on a multiplex immunodot method: The CovidDial study. Seminars in Dialysis, 0, , .	1.3	0
300	Prevalence of Antibodies to COVID-19 Due to Infection or Vaccination in US Adults. Journal of Insurance Medicine (New York, N Y), 2023, 50, 49-53.	0.2	0
301	Risk of COVID-19 after natural infection or vaccination. EBioMedicine, 2023, 96, 104799.	6.1	0
302	Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning. Annual Review of Pathology: Mechanisms of Disease, 2024, 19, .	22.4	2
303	Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan. The Lancet Regional Health - Western Pacific, 2023, , 100911.	2.9	0
304	Immunogenicity and safety of a booster COVIDâ€19 vaccination in patients with chronic liver disease: A multicenter study. , 2023, 2, 127-135.		0
305	Symptom prevalence and secondary attack rate of SARSâ€CoVâ€2 in rural Kenyan households: A prospective cohort study. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	0
306	History of primary-series and booster vaccination and protection against Omicron reinfection. Science Advances, 2023, 9, .	10.3	1

#	Article	IF	Citations
307	Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. EClinicalMedicine, 2023, 64, 102249.	7.1	0
309	Impact of Vaccination and Nonpharmaceutical Interventions With Possible COVID-19 Viral Evolutions Using an Agent-Based Simulation. , 2024, 3, 100155.		0
311	Perinatal Outcomes at Birth in Women Infected and Non-Infected with SARS-CoV-2: A Retrospective Study. Healthcare (Switzerland), 2023, 11, 2833.	2.0	0
312	IVï¼Žæ–°åž‹ã‚³ãƒŠã‚¦ã‚¤ãƒ«ã‚¹æ„Ÿæ¯“ã•ã»Šå¾Œã®å±•æœ›. The Journal of the Japanese Society of Internal Medicine, 2022, 111	0.1	2
313	Efficacy of Messenger RNAâ€“1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
314	Evolution of Humoral and Cellular Immunity Postâ€“Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab. Open Forum Infectious Diseases, 2023, 10, .	0.9	1
315	Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines. Cell Reports, 2023, 42, 113292.	6.4	1
316	Covid-19 Mortality: The Proportionality Hypothesis. SSRN Electronic Journal, 0, , .	0.4	0
318	Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students. Pediatrics, 2023, 152, .	2.1	1
319	Efficacy and safety of mRNA1273 SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Single center experience. Medicina ClÃnica, 2024, 162, 313-320.	0.6	0
320	SARSâ€CoVâ€2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study. Influenza and Other Respiratory Viruses, 2023, 17, .	3.4	1
321	Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19. Nature Immunology, 0, , .	14.5	1
322	Beyond the waves: Unraveling pandemic outcomes with genomic insights and immunity analysis â€“ Evidence from 14 countries. Preventive Medicine, 2024, 178, 107820.	3.4	0
323	Epidemiology of the COVID-19 Pandemic: An Update. , 2024, , 411-426.		0
324	Role of booster vaccines and hybrid immunity against severe COVID-19 outcomes during BA.5 omicron predominance in Thailand. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
325	Factors associated with COVID-19 vaccination coverage in hypertensive patients with Omicron infection in Shanghai, China. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	2
326	Effectiveness of a fourth <scp>SARSâ€CoV</scp>â€2 vaccine dose in previously infected individuals from Austria. European Journal of Clinical Investigation, 2024, 54, .	3.4	1
327	Evaluating the accessibility and capacity of SARS-CoV-2 vaccination and analyzing convenience-related factors during the Omicron variant epidemic in Beijing, China. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0

#	Article	IF	Citations
328	Epidemiology of post-COVID syndrome. Medicinski Podmladak, 2023, 74, 1-5.	0.0	0
329	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	28.6	1
330	Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open, 2023, 13, e076892.	1.9	2
331	Allergic diseases aggravate the symptoms of SARS-CoV-2 infection in China. Frontiers in Immunology, 0, 14, .	4.8	0
332	Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021â€“2022. Swiss Medical Weekly, 2023, 153, 3502.	1.6	0
333	Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar. , 2023, 1, e000479.		0
334	Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines, 2024, 12, 36.	4.4	0
335	Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations. BMC Infectious Diseases, 2024, 24, .	2.9	0
336	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3
337	Risk factors for SARS-CoV-2 infection: a test-negative caseâ€“control study with additional population controls in Norway. BMJ Open, 2024, 14, e073766.	1.9	0
338	Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care Personnel. Open Forum Infectious Diseases, 2024, 11, .	0.9	0
339	Two-year outcomes in patients after hospitalization for COVID-19: data from the TARGET-VIP registry. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3757.	1.4	0
340	Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics. BMJ Global Health, 2024, 9, e013680.	4.7	0
341	Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines. Vaccines, 2024, 12, 57.	4.4	0
342	Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021â€“2022. Vaccines, 2024, 12, 58.	4.4	0
344	Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and TÂcells in protection and disease. Molecular Therapy, 2024, 32, 540-555.	8.2	1
345	Comparative analysis of COVID-19 and influenza prevalence among Egyptian pilgrims returning from Hajj and Umrah in 2022: epidemiology, clinical characteristics, and genomic sequencing. Archives of Public Health, 2024, 82, .	2.4	0
346	Understanding SARS-CoV-2 spike glycoprotein clusters and their impact on immunity of the population from Rio Grande do Norte, Brazil. Infection, Genetics and Evolution, 2024, 118, 105556.	2.3	0

#	Article	IF	Citations
347	Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis. BMC Public Health, 2024, 24, .	2.9	0
348	Omicron BA.2 breakthrough infection elicits CD8 ⁺ T cell responses recognizing the spike of later Omicron subvariants. Science Immunology, 2024, 9, .	11.9	1
349	Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022. Journal of Korean Medical Science, 2024, 39, .	2.5	1
351	Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study. BMC Infectious Diseases, 2024, 24, .	2.9	0
352	Vaccination as a protective factor for medical workers during the COVID-19 pandemic. Science and Innovations in Medicine, 2024, 1, 37-43.	0.1	0
353	Booster vaccination: host preparation against Omicron challenge by innate immunity training. MedComm, 2024, 5, .	7.2	0
355	Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nature Communications, 2024, 15, .	12.8	0
356	Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection. Vaccine, 2024, 42, 1332-1341.	3.8	0
357	SARS-CoV-2, COVID-19, and Children: Myths and Evidence. , 2023, , 503-520.		0
358	Omicron BA.4/5 neutralization and cellâ€mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A followâ€up cohort study. Journal of Medical Virology, 2024, 96, .	5.0	0
360	Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study. Vaccines, 2024, 12, 240.	4.4	0
361	<scp>COVIDâ€19</scp> vaccination: are more jabs needed or are we now immune?. Internal Medicine Journal, 2024, 54, 368-373.	0.8	0
362	Current state of COVID-19 in children: 4 years on. Journal of Infection, 2024, 88, 106134.	3.3	0
364	A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication. Antiviral Research, 2024, 225, 105859.	4.1	0
365	Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1Âyear after third dose vaccination. BMC Medicine, 2024, 22, .	5.5	0
366	Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimation. Frontiers in Medicine, 0, 11, .	2.6	0
368	Effectiveness of 4th doses of bivalent mRNA vaccine in reinfections from October 2022 to October 2023 in a general medicine office in Toledo (Spain). Archives of Community Medicine and Public Health, 2024, 10, 001-006.	0.2	0